Market Cap (In USD)
3.94 Million
Revenue (In USD)
52.79 Thousand
Net Income (In USD)
-2.17 Million
Avg. Volume
8.89 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.0E-4-0.0247
- PE
- -
- EPS
- -
- Beta Value
- 1.003
- ISIN
- US2941121079
- CUSIP
- 294112107
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Sharabura
- Employee Count
- -
- Website
- https://enzolytics.com
- Ipo Date
- 2009-04-08
- Details
- Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
More Stocks
-
BDXBudimex SA
BDX
-
BHAGCHEM
-
0KTS
-
0LIYUnited Rentals, Inc.
0LIY
-
ARYMFArgosy Minerals Limited
ARYMF
-
000676
-
NHPCNHPC Limited
NHPC
-
NILKAMALNilkamal Limited
NILKAMAL